MBX Biosciences Presents Preliminary Phase 1 Data for Obesity Candidate MBX 4291
Bitget2026/11/09 21:30- MBX Biosciences reported 7% mean weight loss at eight weeks in MBX 4291's first eight-person multiple-dose cohort, including two placebo recipients.
- The ongoing, blinded Phase 1 trial recorded no serious adverse events; one participant experienced mild diarrhea, with no nausea or vomiting.
- Twelve-week multiple-dose data for the obesity candidate are expected in the fourth quarter of 2026.
- Canvuparatide, an investigational once-weekly treatment for hypoparathyroidism, is in an ongoing Phase 3 trial targeting 160 patients.
- Cash of $481.6 million is expected to fund operations into 2029.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Client nodes, console, and API were not modified; Chainstack discloses attacker used the ARTEX framework
Elon Musk changes his stance! Tesla (TSLA.US) delays Cybertruck production halt to late summer 2027, just two days after suggesting “refund deposits”
Elon Musk stated that Cybertruck production will be extended until late summer 2027 to clear the order backlog, and Tesla's stock price rose by about 4%.
Japanese dovish policymaker urges "slow down": Price increases are not driven by demand, rate hikes may drag down the economy and inflation
Toichiro Asada, a member of the Bank of Japan's Policy Board, stated that the central bank needs to remain cautious and closely monitor the impact of rate hikes on the economy, as rising interest rates pose the risk of suppressing the inflation trend.
Crypto prices
More
